|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Spectrum of calcific aortic valve disease : pathogenesis, disease progression, and treatment strategies显示文摘 | Freeman RV Otto CM | 2005 | Circulation2005，111，： | 1 |
| 2 | Nephropathy requiring dialysis after percutaneous coronary intervention and the critical role of an adjusted contrast dose显示文摘 | Freeman RV O'Donnell M Share D | 2002 | Am J Cardiol2002，90，15： | 1 |
| 3 | Spectrum of ealcifie aortic valve disease: pathogenesis, disease progression, and treatment strategies 显示文摘 | Freeman RV Otto CM | 2005 | Circulation2005，111，24： | 1 |
| 4 | Nephrophy requiring dial- ysis after percutaneous coronary intervention and the critical role of an adjusted contrast dose显示文摘 | Freeman RV O' Donnell M Share D | 2002 | Am J Cardiol2002，90，10： | 1 |
| 5 | Nephropathy requiring dialysis after percutaneous coronary intervention and the critical role of an adjusted contrast dose显示文摘 | Freeman RV O'Donnell M Share D | 2002 | Am J Cardiol2002，90，10： | 1 |
| 6 | Influence of concurrent renal dysfunction on outcomes of patients with acute coronary syn-dromes and implications of the use of glycoprotein Ⅱ b/Ⅲ a in- hibitors显示文摘 | Freeman RV Mehta RH Badr WA | 2003 | J Am Coll Cardiol2003，41，5： | 1 |
| 7 | Spectrum of calcific aortic valve disease:pathogenesis,disease progression,and treatment strategies显示文摘 | Freeman RV Otto CM | 2005 | Circulation2005，111，： | 1 |
| 8 | Spectrum of calcific aortic valve disease:pathogenesis,disease progression,and treatment strategies显示文摘 | Freeman RV Otto CM | 2005 | Circulation2005，111，24： | 1 |
| 9 | Influence of concurrent renal dysfunction on outcomes of patients with acute coronary syndromes and implications of the use of glycoprotein IIb/IIIa inhibitors显示文摘 | Freeman RV Mehta RH A1 Badr W | 2003 | J Am Coll Cardiol2003，41，： | 1 |
| 10 | Influence of concur- rent renal dysfunction on outcomes of patients with acute coronary syndromes and implications of the use of glyeoprotein//b/IIIa in- hibitors显示文摘 | Freeman RV Mehta RH A1 Badr W | 2003 | J Am Coil Cardiol2003，41，5： | 1 |
| 11 | Nephropathy requiring dialysis after percutaneous coronary intervention and the critical role of an adjusted contrast dose 显示文摘 | Freeman RV O' Donnell M Share D | 2002 | Am J Cardiol2002，90，： | 1 |
| 12 | Glucose metabolism in older adults: A study including subjects more than 80 years of age显示文摘 | GAREIA GV FREEMAN RV SUPIANO MA | 1997 | J Geriatr Soc1997，45，： | 1 |
| 13 | Spectrum of calcific aortic valve disease: pathogenesis, disease progression, and treatment strategies 显示文摘 | Freeman RV Otto CM | 2005 | Circulation2005，111，24： | 1 |
| 14 | Spectrum of calcific aortic valve disease: Pathogenesis, disease progression, and treatment strategie显示文摘 | Freeman RV Otto CM | 2005 | Circulation2005，111，24： | 1 |
| 15 | Spectrum of calcific aortic valve disease: pathogenesis, disease progression, and treatment strategies显示文摘 | Freeman RV Otto CM | 2005 | Circulation2005，111，： | 1 |
| 16 | Acquired aortic stenosis 显示文摘 | Freeman RV Crittenden G Otto C | 2004 | Expert Rev Cardiovasc Ther2004，2，1： | 1 |
| 17 | Influence of concurrent renal dysfunction on outcomes of patients with acute coronary syndromes and implications of the use of glycoprotein lI b/i a inhibitors 显示文摘 | Freeman RV Mehta RH A1 Badr W | 2003 | J Am Coil Cardiol2003，41，5： | 1 |
| 18 | Nephropathy requiring dialysis after percutaneous coronary interven- tion and the critical role of an adjusted contrast dose显示文摘 | Freeman RV O 'Donnell M Share D | 2002 | Am J Cardiol2002，90，5： | 1 |
| 19 | Spectrum of calcific aortic valve disease:pathogenesis,disease progression,and treatment strategies显示文摘 | Freeman RV Otto CM | 2005 | Circulation2005，111，24： | 1 |
| 20 | Nephropathy requring dialysis after percutaneous coronary intervention and the critical role of an adjusted contrast dose显示文摘 | Freeman RV O'Donnell M Share D | 2002 | Am J Cardiol2002，90，10： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员